Biotechnology firm Biocon on Monday said its unit has received marketing authorisation for a biosimilar product from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Biocon Biologics has received marketing authorisation for Yesafili, a biosimilar of Aflibercept, the Bengaluru-based company said in a regulatory filing.
Yesafili, an ophthalmology product, is intended for the treatment of neovascular (wet AMD) age-related macular degeneration among other issues.
It is highly similar to the reference product Eylea (aflibercept).
"This approval will expand our biosimilar offerings to patients across the globe, building on our oncology and diabetes product portfolios," a company spokesperson said.
As per IQVIA sales data, Aflibercept brand sales in the U.K. stood at $790 million.
RECOMMENDED FOR YOU
Mid-Cap Stocks To Buy, Sell, Hold: Ashok Leyland, Biocon, Prestige — Check Target Price
Jul 11, 2025
Lupin, Biocon Leading Gains Amid Trump's Threats Of 200% Tariff On Drug Import
Jul 09, 2025
Biocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease Medicines
Jul 03, 2025
Biocon Aims To Lead Copycat Wegovy Sales In Canada From Next Year
Jul 02, 2025
POPULAR